Vita Life Sciences Limited · ASX:VLS
Vita Life Sciences — H1 2024 Earnings Presentation
17 slides from Vita Life Sciences's earnings presentation, June 2024
Slide 1: Half Year Presentation June 2024
X VITA LIFE VitaHealth’ Half Year Presentation June 2024
Slide 2: Message from Andrew O'Keefe
XN VITA LIFE Andrew O’Keefe We are pleased to report a strong performance for the first six months ended June 2024. Our organisation’s fundamentals remain solid, reflecting the strength of our strategy and product offerings. Despite some economic uncertainties, our results for the first half demonst
Slide 3: About Vita Life Sciences
About Vita Life Sciences Who we are Our Values C.A.R.E Developers and distributors To provide people with Intelligently crafted To provide health solutions Considered approach of premium and therapeutic trusted formulations that formulations, combing that cater to people in Aspirational complementar
Slide 4: Herbs of Gold, VitaHealth, VitaScience brands
herbsofgold Herbs of Gold Herbs of Gold is an Australian brand that was founded in 1989. By utilising traditional evidence combined with the latest research, Herbs of Gold produces premium herbal, mineral, vitamin and superfood products. Retailers: Health Food Stores and Pharmacies Countries Availab
Slide 5: A history that spans almost 80 years
A history that spans almost From VitaHealth’s establishment in 1947 as a single retail pharmacy, to current day where we are a multi- brand and multi-market business, we focus on acting locally but thinking globally. Qovears 1947 VitaHealth was first established as a retail witeHealth supplement 197
Slide 6: Our people, markets & partners
Our people, markets & partners We have over 300 employees in the Vita Life Sciences Group across Australia, Malaysia, Singapore, China, Indonesia and Vietnam. We have teams of qualified naturopaths, nutritionists, herbalists, biotechnologists, and pharmacists. Our products are available across some
Slide 7: Products registered across the business
There are currently over 350 products registered across the business. Australia Herbs of Gold Vitamin k2 180 MAX Herbs of Gold Evening Primrose Oil Daily Herbs of Gold Activated B Stress Herbs of Gold Women’s Liver & Skin Care Herbs of Gold Magnesium Powder High Strength Herbs of Gold Magnesium Nigh
Slide 8: Outstanding industry and customer recognition
Outstanding industry. and customer recognition VY VitaHealth'| BEST BRAND | STAR OUTSTANDING rbsofga BUSINESS AWARDS 2023 j - MALAYSIA. (OICE OF PROGRAM 2023 - AUSTRALIA BEST HEALTH SUPPLEMENT AEON WELLNESS REAL BEAUTY AWARD 2024 - MALAYSIA CONSUMERS’ CHOICE 2023/2024 - SINGAPORE VOICE OF THE CUSTOM
Slide 9: Marketing
Marketing Mivitaneater Our advertising and promotional approach is global but acts local. Reaching millions of consumers, our marketing efforts are across television, digital, social, radio, outdoor, print and in-store. ‘WAKE UP GOLDEN! Ss NA VITA LIFE
Slide 10: Environmental, Social and Governance (ESG) strategy
At Vita Life Sciences, we are dedicated to enhancing our Environmental, Social and Governance (ESG) strategy by embedding initiatives into our business operations to uphold the high standards we set for ourselves and our partners. We have developed partnerships with charities, launched team initiati
Slide 11: Revenue, equity and cash reserves
REVENUE mm $39.5M $6.0M ae UP 9% VS PCP EQUITY y RESERVES $48.7M $27.7M (no borrowing) The Group maintains a strong balance sheet with equity of $48.7 million and cash reserves of $277 million, with no bank borrowings. NAVITA LIFE
Slide 12: The Board is satisfied with the HY June 2024 performance
The Board is satisfied with the HY June 2024 performance. The positive outcomes across Australia, Malaysia and Singapore are expected to continue into the second half of the year. A cautious yet optimistic approach in navigating the China market is expected during the second half. The Group remain f
Slide 13: Half Year Results
Half Year Results Half year ended June 2024 2023 $’m $’m Revenue 39.5 34.4 EBITDA 5.8 5.7 EBIT 5.6 5.4 Profit before tax 6.0 5.5 Profit after tax 4.3 4.0 EPS (Basic – cents/ share) 7.84 7.42 Dividend (cents / share) 3.5 3. 0 13
Slide 14: Balance Sheet
Balance Sheet Balance Sheet as at Jun 2024 Dec 2023 $’m $’m Current assets 56.2 48.3 Non-current assets 11.7 11.5 Total assets 67.9 59.8 Current liabilities 19.0 16.2 Non-current liabilities 0.2 0.3 Total Liabilities 19.2 16.5 Net Assets 48.7 43.3 14
Slide 15: Cash Flow
Cash Flow Cash Flow for the half year ended June 2024 2023 $’m $’m Receipts from customers 40.4 35.3 Payments to suppliers and employees (36.6) (29.3) Gross operating cash flow 3.8 6.0 EBITDA 5.8 5.7 Gross operating cash flow / EBITDA* 65% 105% Net interest 0.5 0.1 Income tax paid (1.6) (1.5) Operat
Slide 16: Andrew O'Keefe and Chin Lkhoo contact details
ANDREW O'KEEFE MANAGING DIRECTOR CHIN LKHOO CHIEF FINANCIAL OFFICER (e) +612 9545 2633 1/102 Bath Road, Kirrawee, NSW 2232 enquiries@vitalifesciences.com.au vitalifesciences.com
Slide 17: Disclaimer
Disclaimer This document has been prepared by Vita Life Sciences Limited (Vita Life Sciences or VLS) and comprises written material/slides for a presentation concerning Vita Life Sciences. The presentation is for information purposes only and does not constitute or form part of any offer or invitati